GlassScriptPhysician profile
Douglas Rahn
NPI 1609018340
$984.01
in general payments reported to CMS, 2019-2025
22 companies · $667 in 2025
The $667 reported for 2025 was more than what 79% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.31 · 2022: $24.75 · 2024: $274 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $146.27 | 2025 | Ninlaro, Fruzaqla |
| Caris Mpi, INC. | $112.21 | 2025 | Mi Cancer Seek |
| Astrazeneca Pharmaceuticals LP | $92.82 | 2024-2025 | Imfinzi |
| Regeneron Healthcare Solutions, INC. | $83.63 | 2024-2025 | Libtayo |
| Karl Storz Endoscopy-America | $59.01 | 2025 | |
| Daiichi Sankyo INC. | $55.53 | 2025 | Datroway, Enhertu |
| Genzyme Corporation | $47.82 | 2024 | |
| Pfizer INC. | $37.93 | 2025 | |
| Abbvie INC. | $34.85 | 2024 | |
| Deciphera Pharmaceuticals INC. | $31.76 | 2025 | Qinlock, Romvimza |
| Eisai INC. | $30.71 | 2024 | |
| Tersera Therapeutics LLC | $28.41 | 2025 | Zoladex |
| Beigene USA, INC. | $27.68 | 2024 | Brukinsa |
| Genmab U.S., INC. | $25.93 | 2024 | Epkinly |
| Tolmar Pharmaceuticals, INC. | $24.75 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $24.47 | 2025 | Pyrukynd |
| Genentech USA, INC. | $24.27 | 2025 | Itovebi |
| Janssen Biotech, INC. | $22.92 | 2025 | Erleada |
| Blueprint Medicines Corporation | $20.82 | 2024 | Ayvakit |
| Boston Scientific Corporation | $18.31 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.55 | 2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $16.36 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Rahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.